CJC 1295 is a synthetic version of the peptide GHRH. This peptide was developed by researchers at ConjuChem in Canada, as a means of creating a more stable version of this peptide, in hopes that it could be used for more long term applications. Initial research into the effectiveness of peptides CJC 1295 in animals indicates that this peptide may be used to improve skin tone, encourage weight loss and build muscle mass.
CJC 1295 has also been shown to be effective in encouraging slow wave sleep. This is the portion of the sleep cycle where memory retention and muscle growth occur, which can be quite valuable to maintaining and improving the structure of the body. CJC 1295 can also be used as an alternative to hormone releasing factor GHRH, though the synthetic peptide has a longer half-life and increased stability when it is applied to the tissues.
Activation of GRF Receptors in the Anterior Pituitary
Bioconjugation of free thiol in vivo of serum albumin can be placed in a reactive group of a bioactive peptide, to extend the life of this chemical within the plasma.
A group of maleimido derivates of GRF 1-29 were bioconjugated in their synthesized forms ex vivo as a means of enhancing their stability against bioactivity, then used to secrete hormone in the anterior pituitary cells of rats.
When these chemicals were administered individually, hormone was measured and CJC 1295 was revealed to provide a 3x release of hormone over the course of two hours.
Western blot analysis of rat plasma exposed to CJC 1295 showed that an immunoreactive species of the serum albumin appeared within 15 minutes of this application and remained in the rat’s circulation for over 24 hours. These results imply that CJC 1295 is stable and can be used to enhance the plasma half-life of hGRF 1-29.
Somatotroph Proliferation and Normal Somatic Growth
Molecular pathways which promote maintenance and proliferation of cells in the anterior pituitary gland are not well understood, but as knowledge of these systems grows it could prove useful for developing treatments for growth disorders.
Mice have been supervised with muscarinic acethlcholine receptor subtypes that were associated with hypoplasia and a decrease in hormone.
The application of CJC 1295 improved the growth deficit in these mice by restoring the size of the pituitary gland and IGF-1 levels.
These findings indicate that M2 receptors are essential to the proper function of hypothalamic GHRH neurons, by promoting the proliferation of pituitary cells.
Normalizing GHRH in Knockout Mice
Those with hormone deficiencies have few treatment options, because many peptides have a short half-life.
CJC 1295 has been found to selectively bind with endogenous albumin when injected, extending the half-life of this product. Administering CJC 1295 has been found to normalize length and weight in mice with injections every 48-72 hours.
In animals treated every 24-48 hours CJC 1295 normalized tibia and femur growth.
Research suggests that applying CJC 1295 may be able to increase GH mRNA and RNA to normalize body composition and growth in mice. These effects become less-effective when the chemical is applied every 48 or 72 hours.
Because research into the effects and potential uses of CJC 1295 is still in its infancy, many suppliers are not yet prepared to provide this chemical to researchers. The amount of CJC 1295 necessary for successful application to live animals has yet to be determined, so researchers will need to read the packaging for this peptide carefully, to determine the most appropriate application methods for the research they are set to perform.